|1.||Cortes, Jorge: 29 articles (11/2014 - 07/2005)|
|2.||Hochhaus, Andreas: 26 articles (11/2015 - 06/2006)|
|3.||Kantarjian, Hagop: 22 articles (11/2015 - 07/2005)|
|4.||Rosti, Gianantonio: 20 articles (09/2015 - 06/2007)|
|5.||Saglio, Giuseppe: 20 articles (09/2015 - 02/2008)|
|6.||Kantarjian, Hagop M: 19 articles (11/2015 - 02/2007)|
|7.||Baccarani, Michele: 19 articles (11/2015 - 06/2007)|
|8.||Jabbour, Elias: 16 articles (12/2015 - 11/2006)|
|9.||le Coutre, Philipp: 16 articles (02/2015 - 11/2007)|
|10.||Hughes, Timothy P: 15 articles (07/2014 - 06/2010)|
|1.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
12/01/2013 - "Nilotinib is an effective option for the first-line treatment of chronic myeloid leukemia (CML) patients in chronic phase (CP). "
08/01/2013 - "Recently, nilotinib has been approved as a first-line treatment for chronic myelogenous leukemia in the US and Japan. "
09/01/2015 - "We report here the long-term, 6-year results of the first investigator-sponsored, GIMEMA multicenter phase 2, single-arm trial with nilotinib 400 mg twice daily as first-line treatment in 73 patients with chronic-phase chronic myeloid leukemia. "
09/01/2015 - "Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia."
01/01/2012 - "First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation."
01/01/2015 - "As a result, the Philadelphia chromosome-positive subclone was eradicated within 1 month; however, disease progressed and was again dominated by the Philadelphia chromosome-negative founding clone, demonstrating rapid clonal expansion under nilotinib-induced selection pressure."
08/20/2011 - "Nilotinib is an effective first-line treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic phase. "
08/20/2011 - "Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase."
12/01/2010 - "Based on the results of the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, the US FDA has granted accelerated approval of nilotinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase. "
06/01/2013 - "Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia."
01/01/2014 - "The purpose of this study was to evaluate the effect of nilotinib on eradicating leukemia stem cells and enhancing the efficacy of chemotherapeutic agents. "
01/01/2014 - "Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells."
12/01/2014 - "Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies."
05/01/2014 - "One patient died five months after starting nilotinib due to progression of leukemia; four patients achieved major molecular response, two patients had reduced expression of BCR-ABL gene. "
01/01/2014 - "Despite poor csf penetration, nilotinib showed significant clinical activity in CNS relapse of BCR-ABL(+) leukemias. "
|4.||Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/01/2015 - "Are Rogerofenib and Nilotinib Effective for Advanced Gastrointestinal Stromal Tumor (GIST) Patients who have Already been Given Main Treatments?"
06/01/2012 - "Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors."
10/15/2011 - "Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor."
09/01/2013 - "Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?"
05/01/2011 - "Efficacy and tolerability of nilotinib in patients with refractory gastrointestinal stromal tumor are briefly discussed."
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/01/2014 - "The first had B-cell acute lymphoblastic leukemia which relapsed in the CNS while maintaining molecular remission in the bone marrow on nilotinib. "
01/01/2014 - "Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia."
05/01/2008 - "Finally, rapid BCR-ABL-reactivation shortly after starting nilotinib treatment was seen in acute lymphoblastic leukemia patients with progressive disease carrying the P-loop mutations Y253H, E255K, or mutation T315I. "
01/01/2007 - "Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia."
09/15/2005 - "AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells."
|2.||dasatinib (BMS 354825)
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
|7.||Bcr-Abl tyrosine kinase
|8.||sorafenib (BAY 43-9006)
|10.||Glucose-6-Phosphate Isomerase (Phosphoglucose Isomerase)
|1.||Stem Cell Transplantation
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Hematopoietic Stem Cell Transplantation
|5.||Transplantation (Transplant Recipients)